Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

House Energy And Commerce Adds Pharma Provisions To Health Reform Bill

Executive Summary

The House Energy and Commerce Committee made a number of changes during markup of the America's Affordable Health Choices Act that will affect the pharmaceutical industry

You may also be interested in...



ASP Calculation Could Get Temporary Revision Under House Reform Bill

Drug wholesalers and physicians could get their wish of having the average sales price calculation for Medicare Part B drugs exclude customary prompt pay discounts, under a provision added to the House Energy and Commerce Committee's portion of health care reform legislation. But the fix, if kept in, would only last five years

ASP Calculation Could Get Temporary Revision Under House Reform Bill

Drug wholesalers and physicians could get their wish of having the average sales price calculation for Medicare Part B drugs exclude customary prompt pay discounts, under a provision added to the House Energy and Commerce Committee's portion of health care reform legislation. But the fix, if kept in, would only last five years

Public-Private CER Institute Amendment Still Alive In House

Although it was not introduced during the House Energy and Commerce Committee's markup of the health care reform bill, an amendment prepared by Rep. Donna Christensen, D-V.I., that would create a public-private institute to oversee comparative effectiveness research activities remains in play and could be a part of the final package that is voted on by the House

Related Content

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel